We want to save patients with severe cancer and autoimmune diseases

Göran Forsberg, CEO
Sep 2022

NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)

Safe Harbor Statement



Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors should not place undue reliance on forward-looking statements. They speak only as at the date of this Investor Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company undertakes no obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.

Cantargia – The IL1RAP company

FIRST IN CLASS ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET

- Five Phase I/II trials, with positive interim data in pancreatic cancer and lung cancer
- Differentiated by broad MOA and unique binding properties
- Synergistic with established therapies

PLATFORM WITH BROAD POTENTIAL TO ADDRESS HIGH UNMET NEEDS

- Target IL1RAP found on most solid tumor forms and leukemias
- IL1RAP signalling key in large number of inflammatory diseases beyond oncology
- Robust patent portfolio on antibody target in oncology (to 2032) and lead asset (to 2035)

INGREDIENTS FOR SUCCESS

- Solid cash position (350 MSEK, 33 MUSD end Q2 2022), plus rights issue for 250 MSEK
- Clear development plan with multiple upcoming catalysts
- Strong management team with experience in bringing products through development to market

Cantargia – Save lives and create value through IL1RAP

Project	Disease	Type of treatment	Discovery phase / Preclinical phase / Clinical phase I / Clinical phase II / Clinical phase III / Commercial phase
CAN04 Nadunolimab	PDAC	1st line	Gemcitabine/nab-paclitaxel
			FOLFIRINOX
	NSCLC	1st line	Cisplatin/gemcitabine
		2nd/3rd line	Docetaxel
	Non-squamous NSCLC	1st/2nd line	Carboplatin/pemetrexed
		1st line	Pembro/carboplatin/pemetrexed
	TNBC	1st/2nd line	Carboplatin/gemcitabine
	Biliary tract cancer	1st line	Cisplatin/gemcitabine
	Colon cancer	3rd line	FOLFOX
	Solid tumors	ICI combo	Pembro
CAN10	Myocarditis; Systemic sclerosis		
CANxx	New opportunities within IL1RAP platform		

PDAC – pancreatic cancer; NSCLC – non-small cell lung cancer; TNBC – triple negative breast cancer; ICI – immune checkpoint inhibitor; Pembro – pembrolizumab

- Potentially more effective treatment against novel target in clinically validated pathway
- First in class platform technology against novel target
- Well-financed to build a broad, diversified pipeline
- Right team and clear plan to position our projects and maximize value

Cantargia

Cantargia addresses NSCLC & PDAC





Non-Small Cell Lung Cancer

2.1m	**Annual global incidences**
12%	**Fraction of cancer incidence**
1.8m	**Annual global mortalities**
18%	**Fraction of cancer mortality**
19%	**Five-year survival rate**

Treatment: *Surgery, Radiation, Chemotherapy, Immunotherapy*



Pancreatic cancer

0.5m	**Annual global incidences**
3%	**Fraction of cancer incidence**
0.4m	**Annual global mortalities**
5%	**Fraction of cancer mortality**
9%	**Five-year survival rate**

Treatment: *Chemotherapy, Surgery, Radiation*

SIGNIFICANT UNMET NEEDS IN LUNG AND PANCREATIC CANCER

Source: WHO, The Global Cancer Observatory 2018

NADUNOLIMAB AND BIOLOGICAL CONTEXT

IL1RAP is overexpressed in most solid tumors

IL1RAP EXPRESSION IN SOLID TUMOR TYPES



IL1RAP-EXPRESSING CELLS IN TUMOR MICROENVIRONMENT



IL1RAP: DISTINCT OVEREXPRESSION IN TUMORS AND LOW NORMAL TISSUE REACTIVITY

NSCLC – non-small cell lung cancer
HNSCC – head and neck squamous carcinoma

Cantargia

Chemotherapy resistance

- Most chemotherapies induce chemoresistance already after a few months of therapy
- Chemotherapy can upregulate both IL-1α and IL-1β
- Blocking IL-1 signalling counteracts chemoresistance in preclinical models
- High blood levels of inflammatory cytokines IL-1 and IL-6 leads to poor gemcitabine efficacy in patients
- IL-1 mediated chemoresistance for several classes of chemotherapy
  - Platinum based chemotherapy, 5FU, Gemcitabine



SEVERAL LINES OF EVIDENCE SUGGEST CAN04 COUNTERACT CHEMORESISTANCE

Nadunolimab mechanism uniquely enhances docetaxel antitumor activity





Nadunolimab with docetaxel in MC38 syngeneic model:

- Nadunolimab blocks both IL-1α and IL-1β and has ADCC activity
- Nadunolimab increases efficacy of docetaxel
- Control antibody blocking only IL-1β does not have the same effect
- Docetaxel increases IL-1α production in vitro
- Highlights importance of blocking both forms of IL-1 to increase docetaxel efficacy

IN CONTRAST TO IL-1B BLOCKADE, NADUNOLIMAB INCREASES DOCETAXEL EFFICACY; CLINICAL INVESTIGATION ONGOING

Rydberg-Millrud et al Cancer Immunology, Immunotherapy 2022, https://rdcu.be/cUz5Y

cantargia

Positive interim data in pancreatic cancer

Nadunolimab combination with Gem/Abraxane in 1st line (ASCO 2022), n=73:

- 33% response rate with durable responses
- Pseudoprogression-like response in 5 (7%) additional patients
- Promising PFS (7.2 mo) and OS (12.7 mo, 42 % events)
- 12 pts on treatment







PFS AND OS LONGER THAN EXPECTED GIVEN HISTORICAL CONTROL

Safety profile is manageable and supports MOA

	Grade 3-4 (n=76)	All grade (n=76)
Hematological TEAE; n (%)		
Neutropenia	49 (65%)	57 (75%)
Leukopenia/WBC decreased	18 (24%)	23 (30%)
Thrombocytopenia	11 (15%)	31 (41%)
Anemia	10 (13%)	37 (49%)
Febrile neutropenia	10 (13%)	10 (13%)
Non-hematological TEAE; n (%)		
GGT increased	13 (17%)	16 (21%)
Hypertension	7 (9%)	10 (13%)
ALT increased	6 (8%)	16 (21%)
Fatigue	6 (8%)	41 (54%)
AST increased	5 (7%)	14 (18%)
Vomiting	5 (7%)	27 (36%)
Cholestasis	4 (5%)	4 (5%)
Hypokalemia	4 (5%)	12 (16%)

- G-CSF is an approved therapy to counteract neutropenia; Incidence of grade 3-4 neutropenia was only 16 % in pts receiving prophylaxis
- Notably, only 1 % peripheral neuropathy grade 3-4 was observed, vs 17% in historical controls. Fit with mechanism of action

ADDING NADUNOLIMAB TO THE CHEMOTHERAPY APPEAR SAFE

Note: Median duration of treatment 5.5 months (ref 3.9 months); most common reasons for termination: gastrointestinal events or general health deterioration. No patients discontinued due to neutropenia.

Combination strategy in NSCLC – Promising efficacy

Efficacy parameter*	All (n=30)**	Non-squamous (n=16)	Squamous (n=13)
ORR [95% CI]	53% [34-72]	56% [30-80]	46% [19-75]
Disease control rate*** (CR+PR+SD) [95% CI]	83% [65-94]	75% [48-93]	92% [64-100]
Median duration of response [95% CI]	5.8 months [3.7-11.2]	11.2 months [NA]	4.1 months [3.4-5.8]
PFS [95% CI]	6.8 months [5.5-8.8]	7.3 months [5.3-13.0]	5.8 months [3.7-7.4]
Median OS [95% CI]	13.7 months**** [NA]	NA	NA
1-year survival [95% CI]	53%**** [26-73%]	NA	NA

*Responses according to RECIST1.1 criteria
**One tumor of unknown histology
***Two patients withdrew early in association with COVID-19
****Based on 37% of events



Nadunolimab combination with Gem/Cis in 1st line:

- 16/30 patients showed objective response including 1 complete response (ORR 53% vs historical control data of 22-28%), 7pts still on treatment
- No major side effects observed except those from chemotherapy or nadunolimab alone. *Neutropenia frequency higher than expected from chemo (but can be treated with dose reductions or G-CSF)*
- Trial expanding - 40 additional patients with non-squamous NSCLC

STRONG INTERIM RESULTS, UPDATE AT ASCO 2022

[1] Schiller et al, N Engl J Med 2002
[2] Scagliotti et al, J Clin Oncol 2008
[3] Gandhi et al, N Engl J Med 2018
[4] Paz-Ares et al, N Engl J Med 2018

Cantargia

Strong signal in non-squamous NSCLC



Nadunolimab combination with Gem/Cis in 1st line:

- Non-squamous NSCLC comprises approx. 75% of NSCLC cases
- 9 of 16 evaluable patients had objective response including 1 complete response (ORR 56% vs historical control data of 19%)
- 8 patients were 2nd line to pembrolizumab monotherapy, with 7 responses
- 40 additional patients to be recruited (combination with carboplatin/pemetrexed)

DEVELOPMENT ADVANCING TOWARDS RANDOMIZED TRIAL EARLY 2023

Summary of nadunolimab cancer therapy

- Most chemotherapies induce chemoresistance already after a few months of therapy. Chemotherapy can upregulate both IL-1α and IL-1β
- Nadunolimab blocks IL-1 signalling and improve chemotherapy in preclinical models
- Clinical interim results of the combination in both pancreatic cancer and non-small cell lung cancer superior to historical controls of only chemotherapy
- Cantargia is advancing development of combination therapy in both pancreatic cancer and non-small cell lung cancer



SEVERAL LINES OF EVIDENCE SUGGEST CAN04 COUNTERACT CHEMORESISTANCE

CAN10 OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE

CAN10 – New asset within autoimmunity/inflammation

- IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36
- Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation)
- Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on scientific rationale, medical need, development opportunity and competition.
- Clinical trial starts early 2023



UNIQUE OPPORTUNITY FOR CAN10 IDENTIFIED IN LIFE-THREATENING DISEASES

CAN10 – Unique properties in preclinical disease models





New data showing efficacy in viral myocarditis





CAN10 shows potential in several autoimmune/inflammatory diseases with high medical need
Phase I planned for early 2023

FINANCIALS, MILESTONES & SUMMARY

Several upcoming value inflection points

Newsflow over next 6-9 months

Nadunolimab (CAN04)

- Update of results for PDAC, NSCLC and Keytruda combination presented at ASCO
- Phase 2/3 Precision Promise (PDAC)
- New preclinical and translational results
- New clinical trials (Interim results, safety)
  - CAPAFOUR PDAC FOLFIRINOX
  - CESTAFOUR Basket trial (NSCLC, CRC, BTC)
  - TRIFOUR TNBC

CAN10

- Preclinical progress
- Development milestones
- …and initiation of clinical trial early 2023

SIGNIFICANT DATA TO SECURE NEWSFLOW

Solid financial position with strong shareholder support

- Cash and cash equivalents SEK 350 M (~$33M) at end Q2 2022
- Fully guaranteed rights issue of 250 MSEK concluded Aug 2022
- Operating expenses SEK 217.6 M (~$20M) in H1 2022
  - R&D - 95% of operating expenses
  - 27 full-time employees
  - Market cap appr 0.6 BSEK, 53 MUSD Sep 23 2022
- Capital structure
  - Ordinary shares (thousands) 166,987
  - Options corresponding to (thousands) 5,687 if exercised (3.3% dilution)

Current owners (30 June 2022)	
4th AP fund	8.8%
Alecta	7.3%
Six Sis AG	7.0%
Swedbank Robur Funds	6.4%
1st AP fund	6.3%
Avanza Pension	5.6%
SEB AB, Luxemburg	3.0%
Handelsbanken fonder	2.4%
Unionen	1.7%
Goldman Sachs	1.5%

Cantargia – The IL1RAP company

FIRST IN CLASS ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET

- Five Phase I/II trials, with positive interim data in pancreatic cancer and NSCLC
- Differentiated by broad MOA and unique binding properties
- Synergistic with established therapies

PLATFORM WITH BROAD POTENTIAL TO ADDRESS HIGH UNMET NEEDS

- Target IL1RAP found on most solid tumor forms and leukemias
- IL1RAP signalling key in large number of inflammatory diseases beyond oncology
- Robust patent portfolio on antibody target in oncology (to 2032) and lead asset (to 2035)

INGREDIENTS FOR SUCCESS

- Solid cash position (350 MSEK, 33 MUSD end Q2 2022), plus rights issue for 250 MSEK
- Clear development plan with multiple upcoming catalysts
- Strong management team with experience in bringing products through development to market